Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10999.144 | 0.6256 | 0.0115 | 0.6880 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10999.144 | 0.6247 | 0.0093 | 0.6880 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10999.144 | 0.5161 | -0.2354 | 0.6880 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 10999.144 | 0.0124 | -0.9966 | 0.6880 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 12379.168 | 1.0353 | 1.1543 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 12379.168 | 1.0387 | 1.1693 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 12379.168 | 1.0013 | 1.0057 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 12379.168 | 0.8870 | 0.5474 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 12379.168 | 0.7690 | 0.1399 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 12379.168 | 0.7142 | -0.0269 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 12379.168 | 0.6422 | -0.2250 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 12379.168 | 0.5934 | -0.3457 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 12379.168 | 0.0157 | -0.9997 | 0.4672 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 10938.144 | 0.8392 | 0.7142 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 10938.144 | 0.7989 | 0.6416 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 10938.144 | 0.8631 | 0.7571 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10938.144 | 0.5302 | 0.1447 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10938.144 | 0.7153 | 0.4895 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10938.144 | 0.5738 | 0.2270 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10938.144 | 0.5342 | 0.1523 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10938.144 | 0.5102 | 0.1065 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 10938.144 | 0.0167 | -0.9452 | 1.1369 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 12333.168 | 0.8379 | 0.4756 | 0.5815 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 12333.168 | 0.7132 | 0.1183 | 0.5815 | |
| MDA-MB-415 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 12333.168 | 0.6068 | -0.1528 | 0.5815 |